Technical Analysis for INVA - Innoviva, Inc.

Grade Last Price % Change Price Change
D 14.56 -2.02% -0.30
INVA closed down 2.02 percent on Monday, March 18, 2024, on 1.5 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Reversal New Lows Setup Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -2.02%
Pocket Pivot Bullish Swing Setup -2.02%
Volume Surge Other -2.02%
Outside Day Range Expansion -2.02%
Oversold Stochastic Weakness -2.02%
Cup with Handle Other -1.09%

   Recent Intraday Alerts

Alert Time
Outside Day about 16 hours ago
Fell Below Previous Day's Low about 16 hours ago
Down 1% about 16 hours ago
60 Minute Opening Range Breakdown about 17 hours ago
10 DMA Resistance about 17 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Innoviva, Inc. Description

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Drugs Asthma Chronic Obstructive Pulmonary Disease Pulmonary Disease Glucocorticoids Antero Combination Drugs Corticosteroid Organofluorides Respiratory Products Fluticasone

Is INVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.865
52 Week Low 10.96
Average Volume 679,154
200-Day Moving Average 14.05
50-Day Moving Average 15.77
20-Day Moving Average 15.15
10-Day Moving Average 14.85
Average True Range 0.38
RSI (14) 31.97
ADX 13.39
+DI 17.87
-DI 18.52
Chandelier Exit (Long, 3 ATRs) 15.52
Chandelier Exit (Short, 3 ATRs) 15.69
Upper Bollinger Bands 15.83
Lower Bollinger Band 14.46
Percent B (%b) 0.07
BandWidth 9.08
MACD Line -0.29
MACD Signal Line -0.26
MACD Histogram -0.0304
Fundamentals Value
Market Cap 933.1 Million
Num Shares 64.1 Million
EPS 0.75
Price-to-Earnings (P/E) Ratio 19.41
Price-to-Sales 3.46
Price-to-Book 1.60
PEG Ratio 0.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.22
Resistance 3 (R3) 15.29 15.14 15.11
Resistance 2 (R2) 15.14 14.97 15.11 15.07
Resistance 1 (R1) 14.85 14.87 14.78 14.78 15.04
Pivot Point 14.70 14.70 14.66 14.67 14.70
Support 1 (S1) 14.41 14.53 14.34 14.34 14.08
Support 2 (S2) 14.26 14.43 14.23 14.05
Support 3 (S3) 13.97 14.26 14.01
Support 4 (S4) 13.90